英国去势抵抗性前列腺癌伴脊柱转移患者中观察与筛查脊柱MRI及预防性治疗脊髓压迫的比较(PROMPTS):一项开放标签、随机对照、3期试验
PROMPTS研究纳入420例无症状脊柱转移的去势抵抗性前列腺癌患者,随机分为对照组(210例)和筛查MRI组(210例)。中位随访22个月,筛查组临床脊髓压迫(cSCC)发生时间未显著改善(HR 0.64,95%CI 0.37-1.11;P=0.12),1年cSCC发生率对照组6.7% vs 筛查组4.3%(差异-2.4%,95%CI -4.2至0.1)。作者认为常规筛查MRI和预防性治疗以避免cSCC并无必要。
要点
- 筛查MRI组31%(61/200)可评估扫描者检出放射性脊髓压迫(rSCC)。
- 筛查组与对照组cSCC发生时间无显著差异(HR 0.64,95%CI 0.37-1.11)。
- 1年cSCC发生率对照组6.7% vs 筛查组4.3%,差异-2.4%(95%CI -4.2至0.1)。
核心结论
- 尽管干预组检出大量rSCC,中位22个月随访时两组cSCC发生率均低,常规筛查MRI和预防性治疗以预防cSCC在无症状去势抵抗性前列腺癌伴脊柱转移患者中并无必要。
研究设计与样本
- 平行组、开放标签、随机对照、3期优效性试验,从英国45家国民健康服务医院招募患者。
- 纳入年龄≥18岁、ECOG体能状态0-2、无症状脊柱转移、无既往SCC、过去12个月未行脊柱MRI的转移性去势抵抗性前列腺癌患者。
- 采用最小化算法(含随机元素)1:1随机分配至无MRI(对照组)或筛查脊柱MRI(干预组),平衡因素包括治疗中心、碱性磷酸酶(正常 vs 升高)、既往系统治疗线数、既往脊柱治疗、胸腹部影像。
- 干预组筛查MRI后24小时内监测严重不良事件;筛查检出rSCC者接受预防性治疗(放疗或手术减压由主治医师推荐)并每6个月脊柱MRI。
- 所有患者每3个月随访,之后在第30和36个月随访;主要终点为意向治疗人群确认的cSCC发生时间和发生率,主要关注随机后1年。
主要发现
- 2013年2月26日至2017年4月25日共随机420例患者,对照组210例、筛查MRI组210例;中位年龄74岁(IQR 68-79),222/420例(53%)碱性磷酸酶正常,中位前列腺特异性抗原浓度48 ng/mL(IQR 17-162)。
- 筛查MRI在干预组200例可评估扫描中检出61例(31%)rSCC。
- 截至数据截止(2020年4月23日),中位随访22个月(IQR 13-31),筛查组cSCC发生时间未显著改善(HR 0.64,95%CI 0.37-1.11;Gray检验P=0.12)。
- 1年cSCC发生率对照组6.7%(95%CI 3.8-10.6;14/210例)vs 筛查组4.3%(95%CI 2.1-7.7;9/210例),差异-2.4%(95%CI -4.2至0.1)。
- 两组中位cSCC发生时间均未达到;筛查后24小时内未报告严重不良事件。
临床怎么用
- 作者认为,在无症状去势抵抗性前列腺癌伴脊柱转移患者中,常规使用筛查MRI和预防性治疗以预防cSCC并无必要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early diagnosis of malignant spinal cord compression (SCC) is crucial because pretreatment neurological status is the major determinant of outcome. In metastatic castration-resistant prostate cancer, SCC is a clinically significant cause of disease-related morbidity and mortality. We investigated whether screening for SCC with spinal MRI, and pre-emptive treatment if radiological SCC (rSCC) was detected, reduced the incidence of clinical SCC (cSCC) in asymptomatic patients with metastatic castration-resistant prostate cancer and spinal metastasis. METHODS: We did a parallel-group, open-label, randomised, controlled, phase 3, superiority trial. Patients with metastatic castration-resistant prostate cancer were recruited from 45 National Health Service hospitals in the UK. Eligible patients were aged at least 18 years, with an Eastern Co-operative Oncology Group performance status of 0-2, asymptomatic spinal metastasis, no previous SCC, and no spinal MRI in the past 12 months. Participants were randomly assigned (1:1), using a minimisation algorithm with a random element (balancing factors were treatment centre, alkaline phosphatase [normal vs raised, with the upper limit of normal being defined at each participating laboratory], number of previous systemic treatments [first-line vs second-line or later], previous spinal treatment, and imaging of thorax and abdomen), to no MRI (control group) or screening spinal MRI (intervention group). Serious adverse events were monitored in the 24 h after screening MRI in the intervention group. Participants with screen-detected rSCC were offered pre-emptive treatment (radiotherapy or surgical decompression was recommended per treating physician's recommendation) and 6-monthly spinal MRI. All patients were followed up every 3 months, and then at month 30 and 36. The primary endpoint was time to and incidence of confirmed cSCC in the intention-to-treat population (defined as all patients randomly assigned), with the primary timepoint of interest being 1 year after randomisation. The study is registered with ISRCTN, ISRCTN74112318, and is now complete. FINDINGS: Between Feb 26, 2013, and April 25, 2017, 420 patients were randomly assigned to the control (n=210) or screening MRI (n=210) groups. Median age was 74 years (IQR 68 to 79), 222 (53%) of 420 patients had normal alkaline phosphatase, and median prostate-specific antigen concentration was 48 ng/mL (IQR 17 to 162). Screening MRI detected rSCC in 61 (31%) of 200 patients with assessable scans in the intervention group. As of data cutoff (April 23, 2020), at a median follow-up of 22 months (IQR 13 to 31), time to cSCC was not significantly improved with screening (hazard ratio 0·64 [95% CI 0·37 to 1·11]; Gray's test p=0·12). 1-year cSCC rates were 6·7% (95% CI 3·8-10·6; 14 of 210 patients) for the control group and 4·3% (2·1-7·7; nine of 210 patients) for the intervention group (difference -2·4% [95% CI -4·2 to 0·1]). Median time to cSCC was not reached in either group. No serious adverse events were reported within 24 h of screening. INTERPRETATION: Despite the substantial incidence of rSCC detected in the intervention group, the rate of cSCC in both groups was low at a median of 22 months of follow-up. Routine use of screening MRI and pre-emptive treatment to prevent cSCC is not warranted in patients with asymptomatic castration-resistant prostate cancer with spinal metastasis. FUNDING: Cancer Research UK.
引用
- Dearnaley D, Hinder V, Hijab A, et al. Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2022. PMID: 35279270. doi:10.1016/S1470-2045(22)00092-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。